» Articles » PMID: 26198368

Pathophysiology and Burden of Infection in Patients with Diabetes Mellitus and Peripheral Vascular Disease: Focus on Skin and Soft-tissue Infections

Overview
Publisher Elsevier
Date 2015 Jul 23
PMID 26198368
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

Diabetes mellitus affects 284 million adults worldwide and is increasing in prevalence. Accelerated atherosclerosis in patients with diabetes mellitus contributes an increased risk of developing cardiovascular diseases including peripheral vascular disease (PVD). Immune dysfunction, diabetic neuropathy and poor circulation in patients with diabetes mellitus, especially those with PVD, place these patients at high risk for many types of typical and atypical infections. Complicated skin and soft-tissue infections (cSSTIs) are of particular concern because skin breakdown in patients with advanced diabetes mellitus and PVD provides a portal of entry for bacteria. Patients with diabetes mellitus are more likely to be hospitalized with cSSTIs and to experience related complications than patients without diabetes mellitus. Patients with PVD requiring lower extremity bypass are also at high risk of surgical site and graft infections. Methicillin-resistant Staphylococcus aureus (MRSA) is a frequent causative pathogen in cSSTIs, and may be a significant contributor to surgical site infections, especially in patients who are colonized with MRSA on hospital admission. Patients with cSSTIs and diabetes mellitus or PVD experience lower clinical success rates than patients without these comorbidities, and may also have a longer length of hospital stay and higher risk of adverse drug events. Clinicians should be vigilant in recognizing the potential for infection with multi-drug-resistant organisms, especially MRSA, in these populations and initiating therapy with appropriate antibiotics.

Citing Articles

Unlocking the role of wound microbiome in diabetic, burn, and germ-free wound repair treated by natural and synthetic scaffolds.

Xu Z, Zhang L, Tang Q, Yang C, Ding X, Wang Z Acta Pharm Sin B. 2025; 15(1):611-626.

PMID: 40041888 PMC: 11873655. DOI: 10.1016/j.apsb.2024.08.024.


Cutaneous Adverse Drug Reactions Associated with SGLT2 Inhibitors.

Mederle A, Dumitrescu P, Borza C, Kundnani N J Clin Med. 2025; 14(1.

PMID: 39797270 PMC: 11721703. DOI: 10.3390/jcm14010188.


Association Between Diabetes Mellitus-Tuberculosis and the Generation of Drug Resistance.

Cornejo-Baez A, Zenteno-Cuevas R, Luna-Herrera J Microorganisms. 2025; 12(12.

PMID: 39770852 PMC: 11728438. DOI: 10.3390/microorganisms12122649.


Urgent call for attention to diabetes-associated hospital infections.

Yu X, Zhou L, Huang X, Li X, Pan Q, Wang M World J Diabetes. 2024; 15(8):1683-1691.

PMID: 39192868 PMC: 11346093. DOI: 10.4239/wjd.v15.i8.1683.


The Complex Immunological Alterations in Patients with Type 2 Diabetes Mellitus on Hemodialysis.

Trandafir M, Savu O, Gheorghiu M J Clin Med. 2024; 13(13).

PMID: 38999253 PMC: 11242658. DOI: 10.3390/jcm13133687.